医学
安慰剂
临床终点
内科学
溃疡性结肠炎
胃肠病学
临床试验
外科
病理
替代医学
疾病
作者
Laurent Peyrin‐Biroulet,Jessica R. Allegretti,David T. Rubin,Brian Bressler,Matthew Germinaro,Kuan-Hsiang Gary Huang,Nicole Shipitofsky,Hongyan Zhang,Rebbecca Wilson,Chenglong Han,Brian G. Feagan,William J. Sandborn,Julián Panés,Tadakazu Hisamatsu,Gary R. Lichtenstein,Bruce E. Sands,Axel Dignaß,О. Аbrahamovych,Halyna Afanasieva,Lilia Aitova
标识
DOI：10.1053/j.gastro.2023.08.038
摘要
The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
ceeray23
归尘
yyds
进击的PhD
Haoru
回忆
要减肥的胖子
无极微光
sxb10101
Singularity
AneyWinter66
情怀
xu
大龙哥886
laber
归去来兮
今天看文献了吗
null
YifanWang
mkeale
浮游
叽了咕噜
若宫伊芙
皖公网安备34019202002308
